EUVIMEDEUVIMED entdecken
Crossref

SEPTIN9 Gene Methylation Ratio as Follow‐Up Biomarker in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Víctor Domínguez-Prieto iD, Rocío Olivera-Salazar iD, Miguel León-Arellano iD, Luz Vega-Clemente iD, Rocío Barrueco-Gutiérrez iD, Cristina Caramés iD, Eva Ruiz-Hispán iD, Raquel Fuentes-Mateos iD, Diana Isabel Rosero-Rodríguez iD, Ignacio Mahillo-Fernández iD, Héctor Guadalajara iD, Mariano García-Arranz iD und 1 weitere

Journal of Surgical Oncology · 2026-11 · 134 (6) · 822-829

DOI: 10.1002/jso.70346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 29.07.2026. Verfasst von Víctor Domínguez-Prieto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain. Hauptthemen laut MEDLINE: Septins, Biomarkers, Tumor, DNA Methylation, Neoadjuvant Therapy. Die Arbeit nennt 26 Literaturangaben. Gefördert von: "Fondo de Investigaciones Sanitarias-ISCIII-FEDER", Ministry of Health, Spain, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are not reliable biomarkers for the assessment of tumor response to total neoadjuvant therapy (TNT) and the early detection of local regrowth or systemic relapse in patients with locally advanced rectal cancer (LARC). Our aim is to evaluate the utility of SEPTIN9 methylation ratio (SEPT9mr) for prediction and assessment of tumor response to TNT and for early diagnosis of local regrowth and systemic metastases in patients with LARC.

Methods

Patients with LARC undergoing TNT were prospectively included. SEPTIN9 methylation status gene in plasmatic cfDNA was determined by ddPCR and expressed as SEPT9mr at 3 times: pre‐treatment, evaluation of tumor response and follow‐up. Association between pre‐treatment SEPT9mr, tumor response to TNT and metastatic risk was explored. Association between SEPT9mr variation between samples and tumor response to TNT, local regrowth and systemic metastases was also explored.

Results

Sixty patients were included. Pre‐treatment SEPT9mr ( p = 0.004) significantly associated with tumor response to TNT, but not with metastatic risk during follow‐up ( p = 0.289). Variation of SEPT9mr during TNT did not significantly associate with tumor response to TNT ( p = 0.130). Variation of SEPT9mr during follow‐up did not associate with the development of local regrowth ( p = 0.533) but significantly associated with the development of systemic metastases ( p = 0.026).

Conclusion

Pre‐treatment SEPT9mr can predict tumor response to TNT, but not the metastatic risk during follow‐up. Variation of SEPT9mr between samples seems to be useful for early detection of systemic metastases during follow‐up but not for evaluation of tumor response to TNT or detection of local regrowth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SeptinsBiomarkers, TumorDNA MethylationNeoadjuvant TherapyRectal NeoplasmsHumansFemaleMaleFollow-Up StudiesMiddle AgedProspective StudiesAgedNeoplasm Recurrence, LocalAdultAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

SEPTIN9 gene methylationliquid biopsylocal regrowthmetastasesrectal cancertotal neoadjuvant therapy

Substanzen

SeptinsSEPTIN9 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • Universidad Alfonso X el Sabio, Madrid, Spain.
  • New Therapies Laboratory, Health Research Institute, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • Oncology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • Biostatistics and Epidemiology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • Universidad Autónoma de Madrid, Madrid, Spain.

ORCID-Profile: Víctor Domínguez-Prieto, Rocío Olivera-Salazar, Miguel León-Arellano, Luz Vega-Clemente, Rocío Barrueco-Gutiérrez, Cristina Caramés, Eva Ruiz-Hispán, Raquel Fuentes-Mateos, Diana Isabel Rosero-Rodríguez, Ignacio Mahillo-Fernández, Héctor Guadalajara, Mariano García-Arranz, Damián García-Olmo

Förderung

  • "Fondo de Investigaciones Sanitarias-ISCIII-FEDER", Ministry of Health, Spain
  • European Regional Development Fund

Zitieren

APA

Domínguez-Prieto, V., Olivera-Salazar, R., León-Arellano, M., Vega-Clemente, L., Barrueco-Gutiérrez, R., Caramés, C., Ruiz-Hispán, E., Fuentes-Mateos, R., Rosero-Rodríguez, D. I., Mahillo-Fernández, I., Guadalajara, H., García-Arranz, M., & García-Olmo, D. (2026). SEPTIN9 Gene Methylation Ratio as Follow‐Up Biomarker in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. Journal of Surgical Oncology, 134(6), 822-829. https://doi.org/10.1002/jso.70346

Vancouver

Domínguez-Prieto V, Olivera-Salazar R, León-Arellano M, Vega-Clemente L, Barrueco-Gutiérrez R, Caramés C, et al. SEPTIN9 Gene Methylation Ratio as Follow‐Up Biomarker in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. Journal of Surgical Oncology. 2026;134(6):822-829. doi:10.1002/jso.70346

BibTeX
@article{DomnguezPrieto2026,
  author = {Domínguez-Prieto, Víctor and Olivera-Salazar, Rocío and León-Arellano, Miguel and Vega-Clemente, Luz and Barrueco-Gutiérrez, Rocío and Caramés, Cristina and Ruiz-Hispán, Eva and Fuentes-Mateos, Raquel and Rosero-Rodríguez, Diana Isabel and Mahillo-Fernández, Ignacio and Guadalajara, Héctor and García-Arranz, Mariano and García-Olmo, Damián},
  title = {SEPTIN9 Gene Methylation Ratio as Follow‐Up Biomarker in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  volume = {134},
  number = {6},
  pages = {822--829},
  doi = {10.1002/jso.70346}
}
Kostenlos starten →